Key clinical point: Presence of autoimmune manifestations (AIMs) predicts poor prognosis irrespective of disease severity in patients with myelodysplastic syndrome (MDS).
Major finding: MDS-associated AIMs were identified in 20% of patients, with overall survival being shorter in patients with vs. without AIMs ( P log-rank = .03). The prognosis was poor and comparable among patients with low-risk MDS and associated AIMs vs. those with high-risk MDS without AIMs ( P log-rank = .9).
Study details: Findings are from a retrospective study of 61 patients with a new diagnosis of MDS.
Disclosures: This research was supported by Grant-in-Aid for Scientific Research(C). The authors declared no conflicts of interest.
Source: Arinobu Y et al. Medicine (Baltimore). 2021 Apr 2. doi: 10.1097/MD.0000000000025406